NEUIMMUNE, INC.

Sykesville, MD · Founded 2020 · CIK 0001860169 · Biotech · Private

Glycoengineered CHO cell lines for manufacturing recombinant alpha-1 antitrypsin (A1AT) with matched post-translational modifications

Grants
$274K
1 award
Sector median: 1
Raised
$125K
2 Form D · Jul 2021
63 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$105,000
Private capital raisedForm D · SEC$20,000
Federal grantDepartment of Health and Human Services · Phase I · Glycoengineering of CHO cells to express recombinant alpha-1 antitrypsin$274,441
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2651ORION THERAPEUTICS INC.—$145K
2652Finch Therapeutics, Inc.—$4.5M
2653TARTAN LLC—$130K
2654NEUIMMUNE, INC.—$125K
2655RESTORE THERAPEUTICS LLC——
2656nVector, Inc.—$125K
2657Sustained Therapeutics Inc.—$100K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Kenneth CarterDirector
  • Thomas FuerstDirector · Executive Officer
  • Mark HankinsExecutive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.